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Background Although human leukocyte antigen (HLA) DQ and DR loci appear to
confer the strongest genetic risk for type 1 diabetes, more detailed information is
required for other loci within the HLA region to understand causality and stratify
additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study
design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci
in all affected sibling pair and trio families, and cases and controls, recruited from
four networks worldwide, for analysis with clinical phenotypes and immunological
markers.
Purpose In this article, we present the operational strategy of training, classifica-
tion, reporting, and quality control of HLA genotyping in four laboratories on three
continents over nearly 5 years.
Methods Methods to standardize HLA genotyping at eight loci included: central
training and initial certification testing; the use of uniform reagents, protocols,
instrumentation, and software versions; an automated data transfer; and the use of
standardized nomenclature and allele databases. We implemented a rigorous and
consistent quality control process, reinforced by repeated workshops, yearly
meetings, and telephone conferences.
Results A total of 15,246 samples have been HLA genotyped at eight loci to four-
digit resolution; an additional 6797 samples have been HLA genotyped at two loci.
The genotyping repeat rate decreased significantly over time, with an estimated
unresolved Mendelian inconsistency rate of 0.21%. Annual quality control exercises
tested 2192 genotypes (4384 alleles) and achieved 99.82% intra-laboratory and
99.68% inter-laboratory concordances.
Limitations The chosen genotyping platform was unable to distinguish many
allele combinations, which would require further multiple stepwise testing to
resolve. For these combinations, a standard allele assignment was agreed upon,
allowing further analysis if required.
Conclusions High-resolution HLA genotyping can be performed in multiple
laboratories using standard equipment, reagents, protocols, software, and
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Introduction
H u m a nl e u k o c y t ea n t i g e n( H L A )g e n e se n c o d ep r o -
teins that present antigenic peptide fragments to T-
cell receptors and are obvious candidates in the
pathogenesis of autoimmune diseases such as type 1
diabetes. Variation in the HLA genes on chromosome
6p21.3 contributes approximately 50% of total
genetic susceptibility to type 1 diabetes [1] and the
region is maximally linked with the log odds ratio
(LOD) score of approximately 116 [2,3]. Although the
class II DQ and DR regions are associated with type 1
diabetes, DP and class I A, B genes also contribute [4–
8]. With 2991 variants presently known (European
Molecular Biology Laboratory-European Bioinfor-
matics Institute ImMunoGeneTics/HLA database ver-
sion 2.20, January 2008, http://www.ebi.ac.uk/imgt/
hla/stats.html),allelesofthehighlypolymorphicHLA
genes differ significantly in frequency among ethnic
populations and in their association with disease. It
remains unclear whether the HLA molecules are
causal, and if so, to what extent, or if they are
marker linked with the true causal genes. Thus, the
Type 1 Diabetes Genetics Consortium (T1DGC) was
organized to conduct a large-scale multinational
project based on families with affected sibling pairs
(ASP) and used comprehensive class I and II genotyp-
ing to provide extended haplotypic information that
is essential to dissect the relative contributions of
specific loci to type 1 diabetes susceptibility, and as a
stratifying factor when studying the effects of new
candidate genes.
Materials and methods
Study populations
For details on recruitment, participation, and initial
sample handling, see the previous articles in this
supplement [9,10]. Figure 1 shows the criteria of
pedigree structure for inclusion of families and Table
1 the number of samples received at the T1DGC
HLA laboratories. All participants gave informed
consent in their own language, with specific assent
procedures for children, and oversight from at least
one ethical review board in each participating
country, in accordance with the Declaration of
Helsinki [9,11]. In addition to the newly recruited
T1DGC families, DNA samples from existing cohorts
of families with type 1 diabetes also were genotyped
by the T1DGC HLA laboratories using identical
protocols, including: HBDI (Human Biological Data
Interchange, Philadelphia, PA, USA); BDA (British
Diabetes Association Warren 1, Cambridge, UK);
Joslin (Joslin Diabetes Center, Boston, MA, USA);
Danish (Steno Diabetes Center, Gentofte, Denmark);
Sardinian (University of Sassari, Sassari, Italy); UK
GRID (United Kingdom Genetic Resource
Investigating Diabetes, Cambridge, UK); and B58C
(British 1958 Birth Cohort from the National Child
Development Study, London, UK).
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Uniform laboratory equipment was provided for all
sites. Equipment included: the Symbol D4000i
barcode reader (Symbol Technologies Inc.,
Holtsville, New York, USA); Applied Biosystems
9600 thermal cyclers for polymerase chain reaction
(PCR; a single exception being the use of the pre-
existing Applied Biosystems 9700 thermal cyclers at
the European laboratory); a BeeBlot hybridization
incubator (Bee Robotics Ltd, Caernarfon, Gwynedd,
Wales, UK) with its operative program; and an
Epson 1670 flatbed scanner (Seiko Epson Corp.,
Nagano, Japan).
Reagents
All laboratories used the same batches of PCR
master-mix, immobilized probe linear arrays (also
known as ‘line strips’), and development reagents,
provided by Roche Molecular Systems (RMS),
Pleasanton, CA, USA [12] with careful documenta-
tion of batch numbers and with inter-batch com-
parisons. The linear arrays used in the T1DGC are
currently not commercially available.
Software
A T1DGC custom-developed HLA Laboratory
System was used throughout for HLA sample and
assay tracking. The web-enabled relational database
system automatically creates 96-well plate grids for
each sample shipment (allowing laboratories to
create new grids for repeats); sample interface files
for StripScan; and supports upload and quality
control (QC) checking of HLA genotype data files
exported from Sequence Complication and
Rearrangement (SCORE) in Extensible Markup
Language (XML) format, delivered through web
page upload to the T1DGC central database at the
Coordinating Center.
StripScan
During the project, RMS developed and made
available the StripScan program for linear array
HLA genotyping analysis. It imports signal inten-
sity for each probe on an array from the flatbed
scanner, detects each probe as positive or negative
(1, 0), and assigns a confidence score to each probe
call. Using a distance algorithm, it determines the
most likely genotypes from the strip pattern and
provides a confidence score for each genotype,
indicating proximity to the observed probe pattern.
This result is reviewed, accepted, or altered by the
laboratory personnel, and a report file containing
the signal intensities and probe calls for each strip is
saved and imported into SCORE for final processing
and transmission of the results.
SCORE
SCORE is a PC-based software program used by
many HLA genotyping laboratories and studies
[13]. SCORE allows for the review of probe binding
patterns and final selection of the accepted HLA
genotype calls. This review is completed prior to
the export of plate grid genotype data in XML
format for transmission and upload to the
Coordinating Center website. The XML file con-
tains the genotype call (two alleles at four-digit
resolution) at eight loci for each sample on the
plate, probe intensities, and probe detection
patterns.
At the Coordinating Center, QC checks of geno-
type data were performed using SAS (SAS Institute,
Cary, NC, USA). The program PEDCHECK (HLA
modified version) [14] was used to identify
Mendelian inheritance errors (MIEs) for single
HLA gene alleles. Extended A-B-C-DRB1-DQ-DP
haplotypes were reconstructed using Merlin
software [15] and checked for obligate
recombination.
Training
After the selection of equipment and development
of protocols, nomenclature, databases, and soft-
ware by the T1DGC-nominated reference
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Figure 1 Pedigree structures for families recruited into the
T1DGC.Darkfillrepresentsafamilymember withtype1diabetes;
no fill, unaffected; and crosshatch may be either. The dotted line
indicates the minimum inclusion criteria for family recruitment
into the T1DGC collection. The maximal included pedigree
structure includes 5 affected and 2 unaffected siblings in affected
sibling pair families; no additional siblings were collected in trio
families. All recruited family members were typed for all HLA loci.
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Research Institute, CHORI), a one-week training
course for the laboratory principal investigators and
technicians from T1DGC networks (Asia-Pacific,
European, and North America) was conducted.
Then, an initial certification testing (ICT) exercise
was performed at each local network laboratory
using a panel of 20 unrelated, mixed-ethnic group,
DNA samples provided by The Fred Hutchinson
Cancer Research Center (Hansen laboratory,
Seattle, WA, USA). This panel had been previously
HLA genotyped to equivalent high resolution by
non-T1DGC HLA laboratories and contained sam-
ples with both common and rare alleles. The local
Table 1 Samples received at HLA genotyping laboratories for new T1DGC and existing cohorts, T1DGC, July 4, 2009
Network or cohort Source network T1DGC laboratory
a Samples received (N)
b
T1DGC affected sibling pair cohorts
Asia-Pacific AP AP 1419
European EU EU 5046
North American NA NA IþNA II 5180
United Kingdom UK EU 1017
Subtotal –– 12,662
T1DGC trio cohorts
Asia-Pacific AP AP 725
European EU EU 42
North American NA NA IþNA II 564
Subtotal –– 1331
T1DGC case cohorts
Asia-Pacific AP AP 0
European EU EU 5
North American NA NA IþNA II 169
Subtotal –– 174
T1DGC control cohorts
Asia-Pacific AP AP 0
European EU EU 2
North American NA NA IþNA II 246
Subtotal –– 248
Existing affected sibling pair cohorts
Danish EU EU 683
Sardinian UK EU 348
BDA Warren I
c UK EU
d 1791
HBDI
e NA NA IþNA II 817
Joslin NA NA IþNA II 384
Subtotal – – 4023
Existing case cohorts
UK GRID
f UK AP
d 570
UK GRID UK EU
d 1518
UK GRID UK NA IþNA II
d 1081
Subtotal – – 3169
Existing control cohorts
B58C
g UK AP
d 350
B58C UK EU
d 782
B58C UK NA IþNA II
d 722
Subtotal – – 1854
Total –– 23,461
aNetwork HLA laboratories (principal investigators) are: Asia-Pacific (AP): Victorian Transplantation and Immunogenetics Service,
Melbourne, Australia (Tait); European (EU): Clinical Chemistry, University Hospital Malmo ¨, Sweden (Carlson); North America (NA): Class
I genotyping, NA I, CHORI, Oakland, CA, USA (Noble); Class II genotyping NA II, RMS, Pleasanton, CA, USA (Moonsamy).
bTotals are shown for each network in the T1DGC for affected sibling pair, trio, case and control cohorts, and for each existing, non-
T1DGC cohort. The European HLA Laboratory genotyped the United Kingdom Network samples. The North American HLA Laboratory
was divided into two physically separate laboratories: NA I and NA II.
cBDA Warren I: British Diabetes Association Warren I.
dSamples typed for HLA–DPA1, –DPB1,– DQA1, and –DQB1 loci only.
eHBDI: Human Biological Data Interchange.
fUK GRID: United Kingdom Genetic Resource Investigating Diabetes.
gB58C: British 1958 Birth Cohort from the National Child Development Study.
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ethnicity of the participants.
The initial standard for certification was 0%
discordance in allele comparisons with existing
genotypes, as judged by the HLA Laboratory QC
Committee. No single laboratory performed with
100% concordance for alleles and as issues con-
cerning data reporting standards, allele nomencla-
ture, and ambiguities became evident, a ‘retraining
workshop’ was organized. Certification criteria
were adjusted to more realistic goals, including
data transmissions that satisfied T1DGC genotype
calling standards; 0% discordance rate at the four-
digit level for disease-critical DQ, DR locus alleles,
with 0% error in two-digit allele group calls and
98% agreement at four-digit allele resolution for
the other five loci. In a second exercise, each HLA
Laboratory typed an identical standard panel of 20
cell line samples selected from the previously
sequence typed DNA samples provided by the
Centers for Disease Control and Prevention (CDC,
Mueller laboratory, Atlanta, GA, USA). The labora-
tories were notified of the ethnicity of the partic-
ipants (three Hispanic, two African American, five
Asian, and 10 Caucasian).
DNA sample handling and tracking
The DNA from the T1DGC families was shipped in
boxes of 92 screw-capped tubes with bar-coded
labels (5mg of DNA at 20ng/mL; total volume
250mL) by the DNA repositories. Family member
samples were grouped on plates whenever possible.
Each plate also contained four water (blank) con-
trols at constant asymmetrical positions, as a way to
determine plate orientation and potential contam-
ination during subsequent processes. The barcodes
for the sample indicate the network of origin, a
family code, and a suffix to indicate father (01),
mother (02), proband (03), or sibling (04–09).
Information on ethnicity also was transmitted.
The laboratories acknowledged the receipt of each
shipment by entry of the shipping forms into the
T1DGC HLA Laboratory System, including scan-
ning of the barcode for each sample. The samples
were spun briefly and pipetted into a 96-well plate
according to a plate grid automatically generated
for the laboratory by the HLA Laboratory System.
Each of the six RMS linear arrays (A, B, C, DQ,
DRB1, and DP) requires a separate 96-well plate.
HLA genotyping
PCR co-amplification of exons 2 and 3 for HLA class
I assays and amplification of exon 2 for HLA class II
was performed using 60ng template genomic DNA,
biotinylated primers, and reagents from RMS in a
60mL reaction mix, and a standardized PCR proto-
col (denaturation at 95 C for 15s, annealing at
60 C for 45s, extension at 72 C for 15s for 35
cycles with an additional 72 C 5min hold and a
15 C hold on an Applied Biosystems 9600 thermal
cycler; as a single exception, the European labora-
tory used 58 C as the annealing temperature for DQ
amplification on the Applied Biosystems 9700
thermal cycler). Using sequence-specific immobi-
lized oligonucleotide probe (SSOP) linear array
technology [12], each biotinylated PCR product
was hybridized to the relevant series of unlabeled
oligonucleotide probes immobilized on nylon-
backed membrane arrays, corresponding to DNA
sequence motifs in a given HLA gene locus, in
linear batches of 48 wells. A full HLA genotype
profile for a single sample required one linear array
each for the A (57 probes), B (81 probes), C (36
probes), DQ (15 DQA1 and 37 DQB1 probes), and
DP (21 DPA1 and 48 DPB1 probes) loci. A low-
resolution DRB1 array (8 probes) identified the
major WLF, WPR, YSTS, VH, YSTG, GYK, KDF, and
EV codon 10–14 motifs as well as two probes each
for the CTLA4 T17A (rs231775) single nucleotide
polymorphisms (SNP) and the INS-23 HphI (rs689)
SNP. For rare homozygotes of the DRB1 *0901 or
*1001 alleles, no further DRB1 genotyping was
required. For other classes, a second high resolution
DRB1 linear array (31 probes) was used following an
allele-specific PCR for each allelic class identified by
the low-resolution array. The BeeBlot automated
hybridization instrument performed a temperature-
controlled program of hybridization and aqueous
washing. After development with streptavidin,
horse radish peroxidase, and substrates, the blue
signals on the array were scanned on a flatbed
scanner and the resulting digital image was pro-
cessed in StripScan software. Results from StripScan
were transmitted to the SCORE program for a final
genotype review, assignment, and approval.
Selection from among all the possible suggested
genotypes was based on experience and consistency
within families and haplotype structure. After the
approval of genotypes at all loci for the 96 samples,
the genotypes and probe call intensities were
uploaded to the Coordinating Center in XML
format using the HLA Laboratory System
(Figure 2). Throughout production, only in North
America (NA), the NA I Laboratory (CHORI)
genotyped all class I loci and NA II (RMS)
genotyped all class II loci.
HLA plate grid and genotype data quality checks
Upon receipt at the Coordinating Center, the XML
data file passed through a software pipeline of data
quality and consistency checks to ensure: (1)
HLA genotyping in the T1DGC S79
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expected plate grid, position, and sample); (2)
consistency with T1DGC HLA nomenclature and
allele calling standards; and (3) genetic inheritance
consistency, using PEDCHECK and Merlin. Data
checks were performed in real time to provide rapid
feedback and implementation of corrective mea-
sures for potential errors.
Quality control
Four samples from a previously genotyped family
were randomly selected by the Coordinating
Center, re-coded, and included in each plate for
continuous QC. HLA laboratories were blinded to
these samples and their identifiers. In addition, all
laboratories participated in an annual QC test in
which each performed single-blind re-genotyping
of an identical panel of 92 samples. These samples
were selected by the Coordinating Center from
approximately 24 ASP families (eight from each
network) and previously typed by one of the
laboratories in normal production, but not previ-
ously used as QC samples. Thus, approximately
one-third of the genotype results provided a test of
intra-laboratory reproducibility and all 92 samples
measured inter-laboratory concordance.
Results
Initial certification testing
Each laboratory (including both NA class I and II
laboratories in North America) typed all loci in
initial certification tests. The results obtained for
the second CDC panel were compared to the
CDC-known reference genotypes (Table 2). Some
discrepancies between the T1DGC consensus geno-
type and the CDC genotype were due to allele
ambiguities, i.e., multiple alleles consistent with
the genotype probe pattern with no distinguishing
sequence motifs on the T1DGC linear arrays (data
not shown in CDC comparison). The consensus
allele calls of all T1DGC laboratories were 99.1%
concordant with CDC calls, with discrepancies in
3/320 allele calls, in B and C class I loci. At two-digit
resolution, the three discrepant alleles were con-
cordant with CDC. Within T1DGC comparisons, 13
total discordant alleles were seen (99.0% overall
concordance), but 7/13 were due to the differences
in ambiguous allele reporting (all DQA1). These
differences highlighted the necessity of standards
for handling allele ambiguity in the T1DGC to
ensure consistency of allele calls between laborato-
ries. After adjusting for ambiguity, the overall
concordance was 99.5% and all remaining allele
discrepancies were in class I loci and consistent at
two-digit resolution. The other result of the ICT
exercises was the development of T1DGC standards
for HLA genotype and allele calling to address
issues of ambiguity and data completeness
(Appendix).
Continuous quality monitoring
The way in which data were acquired for plate
grids, probe intensities, probe binding patterns, and
genotypes enabled analysis of consistency in
reagent batches, changes in protocol, and data
interpretation. Signals for the water controls in
each plate revealed general and specific contami-
nation levels or different array washing stringencies
in laboratories (data not shown). Intra-laboratory
concordance of the repeat genotyping of the inter-
nal blinded QC family samples (four from a single
family per plate) showed an overall allele concor-
dance of 99.3% (Table 3). The discordant alleles
were reasonably evenly distributed across all loci,
although DPA1 had no discrepancies.
Recruitment 
clinic
DNA samples
Whole blood +
cell pack
DNA
Repository
Coordinating
Center
XML
HLA
Laboratory
HLA genotype
data
Shipments and receipts
Figure 2 Simplified process diagram showing HLA genotyping-related specimen and data flow within a T1DGC network (Asia-
Pacific, Europe, North America, and the United Kingdom).
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Three annual QC testing exercises were conducted
from 2005 to 2007. Table 4 shows intra- and inter-
laboratory concordance rates for HLA alleles for all
laboratories. Intra-laboratory discrepancies reflect
the differences between the annual QC result and
the result originally reported by the same laboratory
for the same sample. The three network laboratories
individually showed  99.4% internal concordance
each year. An inter-laboratory discordance occurs if
the resultforoneallelediffersfromthoseofthe other
two laboratories. In both intra- and inter-laboratory
comparisons, multiplediscrepancieswithin thesame
locus and laboratory always occurred within a single
family, often the result of different interpretations of
a single weak probe. In 2006, all laboratories were
concordant for HLA-C in one family, but all were
discordant from the original genotype reported. This
discrepancy was also due to an interpretation of a
single probe and followed intensive review of the
particular genotype. This discrepancy is therefore
reported as intra- and not inter-laboratory
discordance. The three-way inter-laboratory concor-
dance rate per total number of alleles reported was
99.7% for 2005–2007 combined.
Genotype QC analysis: Mendelian inheritance
checks
In each network, a small number of pedigrees
displayed apparent MIEs based on transmission of
alleles and haplotypes from the parents to the
offspring. MIEs may be due to sample mix-up at any
of three handling stages (incorrect registration of
parenthood, incorrect genotyping, or sample con-
tamination); discrepancies between self-reported
and biological familial relationships; or true de
novo mutations. Attempts at resolution involved
multiple steps of review and repeat genotyping. For
pedigrees with inconsistencies at two or less HLA
loci, genotyping was reviewed, repeated, or supple-
mented by DNA sequencing. MIEs at three or more
loci were interpreted as most likely due to sample
mix-up or inconsistency of biological and self-
reported relatedness and were referred to the DNA
Table 3 Intra-laboratory allelic percent concordance for blinded continuousqualitycontroltesting
a,byHLAlocus,T1DGC,July4,2009
Source
network
Plates Quality
control
samples
A B C DPA1 DPB1 DQA1 DQB1 DRB1 SNP
b:
CTLA4
SNP:
INS-23
HphI
All loci
Asia-Pacific 22 87 – – – – – – – – – 98.9 99.9
European 55 219 – 99.1 – – 99.5 – – 98.2 98.6 – 99.5
North American I 60 238 97.9 98.3 99.6 – – – – – – – 98.6
North American II 60 238 – – – – 97.9 99.6 99.2 98.7 99.2 99.2 99.1
United Kingdom 6 24 – – – – – – – – 95.8 – 99.6
Total 143 568 99.1 98.9 99.8 – 98.9 99.8 99.6 98.8 98.9 99.5 99.3
aFour quality control samples are included on each plate. ‘–’ indicates 100% concordance between original and blinded quality control
repeat alleles. Empty cells for North American (NA I and NA II) Laboratories are the HLA class loci that they do not genotype. Identical
samples were assayed separately by NA I and NA II and are only counted once in plate and sample totals. The European Laboratory
genotyped all United Kingdom Network samples.
bSNP: single nucleotide polymorphisms.
Table 2 HLA Laboratory initial certification testing results
a, by laboratory comparison and locus, T1DGC, July 4, 2009
A (%) B (%) C (%) DPA1 (%) DPB1 (%) DQA1 (%) DQB1 (%) DRB1 (%) Total (%)
Comparison
T1DGC vs CDC
b – 1 (97.5) 2 (95.0) – – – – – 3 (99.1)
North American I vs T1DGC – – – – – 2 (95.0) – – 2 (99.4)
North American II vs T1DGC – – – – – – – – –
Asia-Pacific vs T1DGC – 2 (95.0) 1 (97.5) – – 5 (87.5) – – 8 (97.5)
European vs T1DGC – 2 (95.0) 1 (97.5) – – – – – 3 (99.1)
Total – 5 (96.9) 4 (97.5) – – 7 (95.6) – – 16 (98.7)
aAllelic concordance is shown at the allele level for T1DGC consensus genotypes compared to CDC, and individual T1DGC HLA
laboratories compared to the consensus. ‘–’ indicates 100% concordance. Other counts are the numbers of discordant alleles (%
concordance). These results are for the second blinded initial certification testing as described in the text. Each laboratory typed 20
unrelated, mixed-ethnicity samples (40 alleles 8 loci).
bAll discrepancies between T1DGC consensus and CDC are due to ambiguities, i.e., identity within the tested exons.
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possible provision of new samples and repeat
genotyping.
Table 5 shows the cumulative number of MIEs
identified by network cohort and the results of
follow-up analysis. Overall, 3.7% of families (161/
4355 total) contained one or more MIEs, of which
23.0% were most likely due to genotyping errors,
19.9% to sample mix-up, and 51.6% to biological
nonrelatedness. Potential explanations among the
remaining unresolved nine pedigrees (5.6%) with
MIEs may be early sample contamination or de novo
mutation.
Assay repeats
The number of assay repeats performed at each lab-
oratory was also monitored continuously (Figure 3).
The significant trend of decreasing rates of assay
repeats (–0.59% per quarter, p>0.0001) reflects a
learning curve in assay interpretation, consistency
of reagent batches, and resolution of some issues
concerning the identities and quality of DNA
delivered to a laboratory. Linear array-specific
repeat data (Table 6) also reflect the complexity of
interpreting probe patterns for different HLA loci
and the ethnic complexity within the populations
studied. The current cumulative repeat rate is 5.9%.
Discussion
We have implemented processes and systems to
support high volume, high resolution HLA geno-
typing for an international consortium across four
geographically separate HLA laboratories located
on three continents. We standardized operations as
much as possible to eliminate extraneous sources
of variability in assay platform, reagents, assay
conditions, software versions, software interfaces,
and data reporting. When required, the assay
reagent supplier (RMS) rapidly shipped new lots of
reagents to T1DGC HLA laboratories and has
provided comprehensive support to the T1DGC
to ensure the highest quality genotyping results.
Over time, laboratories became more experienced
with the assay, evidenced by the decrease in repeat
assays.
We found that initial laboratory training was
important, but unforeseen issues arose with assay
protocol and genotype reporting, and T1DGC
performed the second ICT exercise. This second
Table 4 Intra- and inter-laboratory results of annual quality control testing of HLA laboratories measured by concordance of alleles in
genotypes compared (n/total and % of total), T1DGC, July 4, 2009
Annual quality control 2005 2006 2007
Quality control sample network source
Total samples 92 90
b 92
AP/EU/NA
a 32/32/28 32/32/26 30/30/32
Total families 25 23 25
AP/EU/NA 9/9/7 8/8/8 8/8/9
Total alleles 1472 1440 1472
AP/EU/NA 512/512/448 512/512/416 480/480/512
Intra-laboratory concordance analysis
Alleles N/total (% concordance)
Asia-Pacific 30/32 (99.6) 30/32 (99.6) 29/32 (99.4)
European 32/32 (100) 32/32 (100) 32/32 (100)
North American
c 28/28 (100) 25/26 (100) 28/28 (100)
Lab: HLA locus Discrepancies (N) EU: B (1) AP: C (2) AP: A (3)
d
NA: DPA1 (1) NA: C (1)
Inter-laboratory concordance analysis
Three-way concordant alleles
N/Total (% concordance)
1470/1472 (99.9) 1431/1440 (99.4) 1469/1472 (99.8)
Lab: Locus discrepancies
from consensus (N)
AP: A (1), B (1) AP: A (1), C (1), DRB1 (1)
EU: C (1), DPB1 (3)
NA: B (1), C (1)
AP: A (1), DPB1 (1)
EU: B (1)
aAP: Asia-Pacific; EU: European; NA: North American.
bTwo samples were not included in results due to sample mix-up in quality control plates.
cNorth American results are the combined total for NA I and NA II laboratories.
dAsia-Pacific reported three discordant A alleles compared to its own original genotyping. However, all three T1DGC labs showed
consensus on the quality control genotyping suggesting the same original allele in all three samples from one Asia-Pacific family was
incorrect.
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Figure 3 Repeated linear array assays for all T1DGC laboratories as a function of calendar time period.
Table 5 Total Mendelian inheritance errors (MIEs) within families and most likely cause, by cohort and laboratory
a, T1DGC, July 4,
2009
Families typed Identifiable (most likely) cause (N and % of all MIEs)
Source of T1DGC/existing
cohort family
Total (N) Number w/MIE (%) Genotyping
error
Sample mix-up Cryptic relatedness Unresolved
T1DGC cohorts
Asia-Pacific 579 26 (4.5) 12 (46.2) 4 (15.4) 6 (23.1) 4 (15.4)
European 1287 23 (1.8) 3 (13.0) 7 (30.4) 13 (56.5) 0 (0.0)
North American I 1385 32 (2.3) 7 (21.9) 15 (46.9) 10 (31.3) 0 (0.0)
North American II 1385 33 (2.4) 8 (24.2) 15 (45.5) 10 (30.3) 0 (0.0)
United Kingdom 169 3 (1.8) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0)
Subtotal 3420 92 (2.7) 32 (34.8) 27 (29.3) 29 (31.5) 4 (4.3)
Existing cohorts
European 225 24 (10.7) 0 (0.0) 0 (0.0) 24 (100.0) 0 (0.0)
North American I 286 5 (1.7) 2 (40.0) 1 (20.0) 2 (40.0) 0 (0.0)
North American II 286 6 (2.1) 3 (50.0) 1 (16.7) 2 (33.3) 0 (0.0)
United Kingdom 424 37 (8.7) 0 (0.0) 4 (10.8) 28 (75.7) 5 (13.5)
Subtotal 935 69 (7.4) 5 (7.2) 5 (7.2) 54 (78.3) 5 (7.2)
Total 4355 161 (3.7) 37 (23.0) 32 (19.9) 83 (51.6) 9 (5.6)
aResults are reported as number of families with  1 MIE (N) and percentage of total MIEs (%) and shown for each HLA Laboratory,
stratified into T1DGC and existing cohort families. In NA, separate HLA Laboratories genotype HLA class I and class II linear arrays, but
results for the NA IþNA II Laboratories are combined and North American families are counted once. Sample mix-up means prior to
HLA Laboratory sample handling, i.e., at the recruitment clinic or network DNA Repository. Cryptic relatedness means that there is most
likely a discrepancy between self-reported and biological relatedness within the genotyped family. The European Laboratory assayed the
United Kingdom T1DGC and existing cohort family samples.
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panel testing to establish laboratory expertise and
familiarity with the study protocols and to test
processes.
Annual laboratory testing through a periodic
blinded QC testing process, after the completion of
the ICT panels at the beginning of genotyping
operations, enabled us to compare inter-laboratory
variation as well as variation within a laboratory
over time. Thus, we could monitor long-term
quality and estimate cumulative error rates. The
blinded retesting of laboratories is similar to a
periodic re-accreditation process for laboratory cer-
tification, such as used by the American Society of
Histocompatibility and Immunogenetics (http://
www.ashi-hla.org) and University of California at
Los Angeles (UCLA) Exchange programs (http://
www.hla.ucla.edu/cellDna.htm). Comparison of
annual QC results from 2005 to 2007 showed
consistently high rates of intra- and inter-labora-
tory concordance with no evidence of a significant
trend. Out of the total eight intra-laboratory dis-
cordances in three years, only one was for a class II
locus. For inter-laboratory discordances, only 5/14
were for class II. The greater discordance rate for
class I (A, B, and C) loci was not surprising, given
the greater locus allelic diversity and larger num-
bers of probes on the arrays. Further analysis of the
familial distribution of discordant alleles also
revealed that the error rates depend critically on
the family structure, which influences the number
of copies of an allele in a family. Error rates were
higher for single copy alleles not transmitted by
parents to offspring or for families without
recruited parents.
Monthly conference calls included the assay and
reagent supplier; their inclusion permitted coordi-
nation of shipments and direct communication of
assay performance. An example of an assay adjust-
ment was a slight change in the hybridization
temperature to resolve selective allele dropout and
faint array probes. Strong cooperation between the
laboratories meant that we were able to compare
experiments in the different laboratory
environments to verify the conditions under
which allele problems occurred and yielded much
more standardized calls of alleles.
We invested significant time and resources to
develop software and standardized computer sys-
tems, which was a considerable upfront cost to the
study. This investment brought benefits, including:
consistent data reporting; streamlined laboratory
data entry, and assay setup; reduced effort by labo-
ratory staff and analysts to manually compile
data and generate reports; and accurate final
data sets for analysis. Many of these benefits are
easily overlooked once these systems are
operational.
Distributed HLA genotyping across laboratories
in multi-center studies permits assessment of inter-
laboratory variability of assays compared to a single
centralized laboratory and improves geographical
proximity to recruiting centers. This structure
minimizes transportation and administration costs
(especially costs associated with government
approval of export of biological specimens and
extra coordination of sample shipments) and
sample degradation or mishandling. However,
some may decide that these advantages are more
than outweighed by the disadvantages of addi-
tional coordination of study assay quality and
organizational complexity, and adopt the alterna-
tive model of a single centralized core laboratory
instead. Many of the QC issues raised are still
pertinent and the solutions adopted in the T1DGC
would be appropriate and easier to implement and
monitor in a single laboratory organization.
Limitations
The HLA genotyping process used a single PCR
reaction to generate co-dominant sequence tem-
plates at exons 2 and 3 for each class I locus, and
exon 2 for each class II locus. A restricted number of
probes interrogate most nucleotide polymor-
phisms; therefore, allelic variation outside of the
Table 6 Percent repeated assays, by HLA linear array type and laboratory
a, T1DGC, July 4, 2009
Source Samples A B C DQ DP DRB1 (low) DRB1 (high) Total (%)
Asia-Pacific 3064 10.9 7.6 8.8 9.9 6.5 9.7 7.2 8.6
European 5778 5.5 2.3 5.3 4.9 2.1 5.9 4.1 4.3
North American (class I) 9163 9.7 7.6 9.7 – – – – 9.0
North American (class II) 9163 – – – 6.8 4.5 3.9 5.6 5.2
United Kingdom 4674 3.6 6.2 3.4 11.0 8.8 1.6 1.7 5.2
Total 22,679 5.3 3.8 5.0 5.3 3.3 4.0 3.7 5.9
aNorth American sample repeats are stratified into class I and class II, corresponding to North American I and North American II
laboratories; empty cells are HLA class loci that they did not genotype. The total sample count includes the North American samples
once. The European Laboratory assayed the United Kingdom Network samples.
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probe within the analyzed exons is not detected.
Uncertainty concerning which allele contains a
particular polymorphism may also exist. The pro-
cess produces a probe pattern that is compatible
with more than one allele combination, i.e.,
allele calling may be ambiguous. To obtain a
completely unambiguous genotype would require
multiple PCR reactions and linear arrays with many
more probes per locus or the use of alternative
technology such as resequencing. These were either
not available or not feasible, because of cost at the
commencement of the study. T1DGC laboratories
elected to select the most likely genotype call, using
information from family allele transmissions and
observed allele frequencies; a standard allele desig-
nation for ambiguous groups of alleles was used.
The likelihood of an incorrect allele assignment will
be the subject of review at the completion of the
study.
Conclusions and recommendations
The lessons learned by the international T1DGC in
setting up distributed laboratory HLA genotyping,
and the general procedures implemented to main-
tain the highest possible assay quality and repro-
ducibility, are relevant to any national or
international multi-center study confronted with
the challenge of managing assay quality across
separate laboratories. The distribution of HLA
genotyping among several laboratories has
increased some administrative tasks, but has
reduced shipping costs, reduced sample damage
during shipping, and has facilitated governmental
approval for export of biological samples as com-
pared to a single central laboratory. It exposed
weaknesses in the processes for reporting assay
results, enabled assessment of inter-laboratory var-
iability of assays, and improved understanding of
technical problems.
The complexity and variability of the HLA
genome region has limited the number of samples
or resolution of genotyping in previous reports of
HLA association with disease, such that the results
obtained with different technologies are not always
comparable. The T1DGC implemented processes
and systems that supported high resolution,
four-digit HLA genotyping at eight loci with a
remarkably high level of consistency across four
international laboratories on multiple continents.
This level of consistency was achieved through the
use of uniform reagents, protocols, instrumenta-
tion, software, automated data transfer, continuous
QC, and communication. The simultaneous geno-
typing of multiple participant family members
enabled accurate haplotype reconstruction and
was of great importance for correct genotyping.
In the T1DGC, the Coordinating Center devel-
oped a centralized, web-deployed sample shipment
and laboratory assay tracking system that the
laboratories integrated with their local laboratory
management system. Since there are few off-the-
shelf software packages that adequately address
international sample shipment functions for multi-
center studies without requiring the implementa-
tion of complex corporate inventory and shipping
packages, the T1DGC almost invariably required
custom software development. The RMS system
used in the T1DGC is a non-commercial expanded
version of a commercial product and so differences
in experience with the specific HLA assays were
expected.
In addition to the large, newly recruited T1DGC
cohort, additional genotyping performed by the
samemethodonsamplesfromotherexistingcohorts
will complement available results to create a large
homogeneous database for current and future statis-
tical analysis. To date, the consortium has generated
HLA genotypes for over 22,000 samples with an
overall concordance of >99.3% achieved.
We offer the following recommendations for
large studies, recognizing that the implementation
will depend on the scope, organization, and goals
of the study.
(1) Standardize assay platform and protocol for all
laboratories. If possible, use identical technol-
ogy and laboratory instruments (manufacturer
and version).
(2) Utilize barcode labeled tubes and readers to
minimize data entry of identifiers, with bar-
code reading software to provide checksum-
based error checks on scans to reduce data
entry errors.
(3) Develop common processes and software to
manage transmission of sample shipment and
assay result data between the laboratories and
the Coordinating Center.
(4) Automate data transfer between software
programs wherever possible. Again, this
automation will usually require custom
software development to build programmatic
interfaces, but will reduce or eliminate the
need for data re-entry and data errors.
(5) Standardize software, allele calling database,
and algorithms used to analyze assay data.
(6) Conduct pre-production training. Labora-
tories often use different assay protocols and/
or technology and have less experience with
methods in use elsewhere. In HLA genotyping,
different methods exist including sequencing
and SSOP genotyping.
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tification or proficiency test using common
samples with known assay titers or assay
results. For HLA genotyping, use a common
panel of DNA samples previously genotyped
to comparable resolution. Require each labo-
ratory to demonstrate initial proficiency in
the assay procedures, before performing pro-
duction assays on participant samples.
Laboratories may need to repeat this exercise
with new panels of samples if the first ICT
reveals lower than desired concordance of
assay results. Develop realistic certification
metrics prior to testing.
(8) Implement a rigorous and continuous QC
program. Over the lifetime of a multi-year
project, there can be a longitudinal drift in the
assay quality and reproducibility. This drift
may be associated with readily identifiable
factors such as new technical staff, changes in
laboratory environment, changes in reagent
batches, or less obvious reasons.
(9) Define standards for assay analysis and data
reporting to the Coordinating Center. In the
case of HLA genotyping, these standards
should cover representation of alleles (digit
resolution, with or without locus prefix,
homozygotes); genotyping platform resolu-
tion-dependent allele ambiguities; and strat-
egy for handling new alleles. The standards
will eliminate confusion and ensure that the
study database maintains consistent power for
analysis.
(10) Implement a system of QC checks in the
Coordinating Center, after laboratories have
performed their analysis of raw assay data and
transmitted the results to the Coordinating
Center. The system should verify that the
reported data meets study assay reporting
standards, and may repeat QC performed in
the laboratories, perhaps with additional auto-
mation not possible locally. For genotyping,
these checks could include tests of Hardy–
Weinberg Equilibrium, Mendelian Inheri-
tance, cryptic sample duplicates (sample mix-
ups) or sample familial relationships, sample
contamination, and sample biological sex.
(11) Plan for ongoing review of the best laboratory
practicesandassayperformanceissuesthrough
regular meetings and conference calls.
The management of laboratory assay quality is
an important consideration for any large study, but
is especially challenging in a study with multiple
laboratories. Implementation of standard processes
and QC procedures can significantly improve assay
and data quality, but can be a complex
undertaking, requiring compromise, flexibility,
and, above all, regular communication.
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Appendix: T1DGC HLA genotype and
allele calling standards
(1) Genotype calls must be reported with full
four-digit resolution. Non-coding change var-
iants should not be reported (i.e., no five or
six-digit resolution alleles).
(2) Two alleles for each locus must be explicitly
reported to the Coordinating Center, includ-
ing homozygotes.
(3) Alleles that are ambiguous using the approved
assays will be reported as the lowest numerical
allele in the ambiguity group.
1
(4) Newly discovered alleles will be assigned a
temporary designation based on the closest
existing allele (by sequence) prior to sequenc-
ing, registration, and receipt of a new official
allele designation from the International
Immunogenetics HLA Database Project
IMGT/HLA (http://www.ebi.ac.uk/imgt/hla).
Sequencing and registration are not obligatory
within the T1DGC, although laboratories may
collaborate with the recruiting investigator to
characterize new alleles.
(5) The same version of the HLA allele database
[16] must be used in the HLA genotype calling
software in all laboratories (StripScan and
SCORE), with synchronized updates across
laboratories.
(6) All probes must be called present or absent
consistent with the final genotype, and not
left indeterminate (i.e., ‘weak’ setting). The
probe binding pattern (string of all probe
detection calls for a linear array) and probe
intensities must be transmitted to the
Coordinating Center with the genotypes.
Note
1. The National Marrow Donor Program system [17]
to identify intermediate resolution ambiguous
allele groups (http://bioinformatics.nmdp.org/
HLA/Allele_Codes/Allele_Code_Lists/index.html)
was not utilized in this study due to incompatibility
with the allele databases and genotyping kits in the
software version used and difficulties in validating
allele group membership.
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